Avalyn Pharma (AVLN): 10% owner sold ~$1.45M

~$1.45M

Approx. value · 48K sh @ $30.28

2.06M

Holds after · shares reported

Traded

Nov 10, 2026

Filed

Nov 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 15, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Avalyn Pharma Inc. (the “Company”), the Board appointed Robert Meyer, M.D. to the Board as a Class II director for an initial term expiring at the annual meeting of stockholders in 2028.”
2. Nov 9, 2026Insider · 1 personInsiders: 2 sales (~$5.1M)
3. Nov 10, 2026 · this disclosureInsider · 2 days before results10% owner sold ~$1.45M of AVLN shares in the open market

What came next

1. Nov 10, 2026Insider10% owner sold ~$165K of AVLN shares in the open market
2. Nov 12, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Avalyn Pharma

For Avalyn Pharma, OQRO holds 4 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AVLN page.

Other recent filings by FMR LLC, 10% owner

• SEC Form 4 at Avalyn Pharma (AVLN)Nov 12, 2026
• SEC Form 4 at Avalyn Pharma (AVLN)Nov 12, 2026
• SEC Form 4 at Avalyn Pharma (AVLN)Nov 12, 2026
• SEC Form 4 at Beam Therapeutics (BEAM)Aug 1, 2025
• SEC Form 4 at Sana Biotechnology (SANA)Jan 10, 2025

The full history of FMR LLC, 10% owner is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Avalyn Pharma

• SEC Form 13F-HRNov 13, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its AVLN page.